The drug Qsymia is a combination of two already known substances – phentermine and topiramate. In June 2023, it was approved by the US Food and Drug Administration. In clinical studies, Qsymia was shown to be dose-dependent. Weight loss could range from 5% when using the minimum dose to 10% at the maximum. In most studies, the drug was prescribed along with mandatory lifestyle changes.
The drug is prescribed to adult patients to reduce excess body weight as an adjunct to diet and exercise, while suffering from high blood pressure or type 2 diabetes, or having high cholesterol. Any of these diseases may be an indication for the use of the new drug.
Active ingredient: phentermine and topiramate
Prescription drug
